Welcome to our dedicated page for Relay Therapeutics news (Ticker: RLAY), a resource for investors and traders seeking the latest updates and insights on Relay Therapeutics stock.
Relay Therapeutics, Inc. (Nasdaq: RLAY) is a clinical-stage precision medicine company that regularly issues news about its small molecule programs for cancer and genetic disease. Company updates frequently highlight progress for its lead PI3Kα program, RLY-2608, also referred to as zovegalisib, and the use of its Dynamo® platform to address challenging protein targets.
Investors and followers of RLAY news can expect detailed announcements on clinical trial milestones, including interim and subset analyses from the ReDiscover first-in-human study and the Phase 3 ReDiscover-2 trial in HR+/HER2- breast cancer with PI3Kα mutations. Press releases have described efficacy measures such as progression-free survival and objective response rates, as well as safety and tolerability profiles for zovegalisib or RLY-2608 in combination with agents like fulvestrant and CDK inhibitors.
Relay Therapeutics also issues corporate and financial updates, such as quarterly financial results, cash runway commentary, and changes to its Board of Directors. These items are often accompanied by Form 8-K filings and may include information on research and development spending, general and administrative expenses, and net loss figures, without serving as investment advice.
Additional news items cover participation in healthcare and biotechnology investor conferences, where company management joins fireside chats hosted by firms such as Jefferies, Goldman Sachs, Wells Fargo, Guggenheim and Morgan Stanley. These events provide further context on strategy, the Dynamo platform, and the clinical pipeline, including programs for NRAS-driven solid tumors and Fabry disease.
This news page aggregates such disclosures so readers can follow Relay Therapeutics’ clinical progress, scientific presentations at meetings like ASCO and SABCS, and ongoing corporate developments related to the RLAY stock.
Relay Therapeutics (Nasdaq: RLAY) reported subset efficacy from its ReDiscover program for zovegalisib (RLY-2608) + fulvestrant presented at SABCS 2025. In a 52-patient efficacy cohort (600mg BID fasted, no PTEN/AKT co-mutation; data cut-off Oct 15, 2025; median follow-up 20.2 months), median PFS was 10.3 months overall and 11.4 months in 2L patients. Among 31 patients with measurable disease, ORR was 39% (47% in 2L). Prior SERD patients showed PFS 11.4 months (ORR 44%); ESR1-mutant patients showed PFS 8.8 months (ORR 60%). Safety remained mostly low-grade and manageable.
Relay Therapeutics (Nasdaq: RLAY) reported third quarter 2025 results and corporate updates on November 6, 2025.
Key items: $596.4 million in cash, cash equivalents and investments as of September 30, 2025; the company expects this cash runway to fund operations into 2029. Continued clinical execution across three RLY-2608 trials, including the Phase 3 ReDiscover-2 trial in PI3Kα-mutated HR+/HER2- advanced breast cancer, ongoing Phase 1/2 ReDiscover triplet cohorts, and the Phase 1/2 ReInspire vascular malformations trial. Board additions: Lonnel Coats and Habib Dable appointed on November 4, 2025.
Financials: Q3 2025 R&D expenses were $68.3M (down from $76.6M YoY); G&A was $12.1M (down from $19.8M YoY); net loss was $74.1M or $0.43 per share (vs $88.1M, $0.63 a year earlier).
Relay Therapeutics (Nasdaq: RLAY) announced management will participate in two investor fireside chats in November 2025. Guggenheim’s 2nd Annual Healthcare Innovation Conference is scheduled for Monday, November 10, 2025 at 11:00–11:25 a.m. ET. Jefferies 2025 Global Healthcare Conference is scheduled for Wednesday, November 19, 2025 at 11:30–11:55 a.m. ET (4:30–4:55 p.m. GMT).
The sessions will be webcast live and accessible via Relay Therapeutics’ investor Events page at https://ir.relaytx.com/news-events/events-presentations. An archived replay will be available for up to 30 days after each event.
Relay Therapeutics (Nasdaq: RLAY) will report third quarter 2025 financial results and corporate highlights after U.S. financial markets close on Thursday, November 6, 2025.
The company is a clinical-stage precision medicine firm combining computational and experimental technologies in drug discovery and is based in Cambridge, Mass.
Relay Therapeutics (NASDAQ:RLAY), a clinical-stage precision medicine company focused on developing therapies for cancer and genetic diseases, has announced its participation in two major investor conferences in September 2025.
Management will engage in fireside chats at the 2025 Wells Fargo Healthcare Conference on September 4 at 2:15 p.m. ET and the Morgan Stanley 23rd Annual Global Conference on September 10 at 11:30 a.m. ET. Both presentations will be available via webcast on the company's investor relations website, with replays accessible for 30 days after the events.
Relay Therapeutics (NASDAQ:RLAY) reported Q2 2025 financial results and clinical updates, highlighting progress in its cancer treatment programs. The company's lead candidate RLY-2608 demonstrated promising results in Phase 1b trials for breast cancer, showing a 10.3-month median progression-free survival and 39% objective response rate in PI3Kα-mutated, HR+/HER2- metastatic breast cancer patients.
The company has initiated its Phase 3 ReDiscover-2 trial comparing RLY-2608 + fulvestrant versus capivasertib + fulvestrant in HR+/HER2- breast cancer patients. Financial results showed a net loss of $70.4 million ($0.41 per share) and cash reserves of $656.8 million, expected to fund operations into 2029.
Relay Therapeutics (NASDAQ:RLAY), a clinical-stage precision medicine company, announced it will release its Q2 2025 financial results and corporate updates after market close on Thursday, August 7, 2025.
The company, which specializes in combining computational and experimental technologies for drug discovery, will provide details on its financial performance and business progress.
Relay Therapeutics (NASDAQ: RLAY), a clinical-stage precision medicine company, has announced its participation in two major investor conferences in June 2025. The company's management will engage in fireside chats at the Jefferies Global Healthcare Conference on June 4 at 8:45 a.m. ET and the Goldman Sachs Global Healthcare Conference on June 11 at 2:40 p.m. ET. Both presentations will be accessible via live webcast through Relay's website, with recordings available for 30 days after each event.
FAQ
What is the current stock price of Relay Therapeutics (RLAY)?
What is the market cap of Relay Therapeutics (RLAY)?
